Sept 29 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO
* Comprehensive mortality review concludes deaths in aura-lv study appear to be unrelated to study drug and consistent with complications of ln
* Announces that Voclosporin achieves primary and all pre-specified secondary endpoints in its phase IIB Aura-LV study for Lupus Nephritis (ln) Source text for Eikon: ID:nBw9SYKnga Further company coverage: AUP.TO